Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Dyslipidemia and cardiovascular complications are comorbidities of nonalcoholic fatty liver disease (NAFLD), which ranges from simple steatosis to nonalcoholic steatohepatitis, fibrosis, and cirrhosis up to hepatocellular carcinoma. Lipoprotein(a) (Lp(a)) has been associated with cardiovascular risk...

Full description

Bibliographic Details
Main Authors:	Marica Meroni, Miriam Longo, Rosa Lombardi, Erika Paolini, Chiara Macchi, Alberto Corsini, Cesare R. Sirtori, Anna Ludovica Fracanzani, Massimiliano Ruscica, Paola Dongiovanni
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2022-03-01
Series:	Hepatology Communications
Online Access:	https://doi.org/10.1002/hep4.1830

Similar Items

Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
by: Marica Meroni, et al.
Published: (2022-09-01)

The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
by: Erika Paolini, et al.
Published: (2023-03-01)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
by: Paola Dongiovanni, et al.
Published: (2021-10-01)

A narrative review about cognitive impairment in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Another matter to face through a holistic approach
by: Marica Meroni, et al.
Published: (2025-02-01)

Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution
by: Miriam Longo, et al.
Published: (2022-03-01)

α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
by: Miriam Longo, et al.
Published: (2021-09-01)

MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD
by: Marica Meroni, et al.
Published: (2020-07-01)

Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease
by: Marica Meroni, et al.
Published: (2020-08-01)

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
by: Serena Pelusi, et al.
Published: (2016-01-01)

Pollution from fine particulate matter and atherosclerosis: A narrative review
by: Chiara Macchi, et al.
Published: (2023-05-01)

Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
by: Annalisa Cespiati, et al.
Published: (2022-01-01)

An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
by: Annalisa Cespiati, et al.
Published: (2023-02-01)

Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?
by: Isabella Fichtner, et al.
Published: (2024-12-01)

Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin
by: Marica Meroni, et al.
Published: (2024-05-01)

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro ModelsSummary
by: Miriam Longo, et al.
Published: (2022-01-01)

The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
by: Nadia Panera, et al.
Published: (2021-03-01)

Genetics Is of the Essence to Face NAFLD
by: Marica Meroni, et al.
Published: (2021-09-01)

Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
by: Elena Buzzetti, et al.
Published: (2015-01-01)

Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease.
by: Anna Ludovica Fracanzani, et al.
Published: (2016-01-01)

The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.
by: Luca Valenti, et al.
Published: (2012-01-01)

Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease
by: Kouichi Miura, et al.
Published: (2021-02-01)

Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease
by: Cheng-Maw Ho, et al.
Published: (2019-04-01)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
by: Erica Gianazza, et al.
Published: (2023-06-01)

Evaluation of fibrosis in patients with nonalcoholic fatty liver disease
by: Aldo J. Montaño-Loza
Published: (2022-01-01)

Peroxisome Proliferator-Activated Receptor Genetic Polymorphisms and Nonalcoholic Fatty Liver Disease: Any Role in Disease Susceptibility?
by: Paola Dongiovanni, et al.
Published: (2013-01-01)

The i148m <it>Pnpla3</it> polymorphism influences serum adiponectin in patients with fatty liver and healthy controls
by: Valenti Luca, et al.
Published: (2012-08-01)

Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
by: Rosa Lombardi, et al.
Published: (2021-02-01)

Transaminases and gamma glutamyl transpeptidase for detecting nonalcoholic steatohepatitis and fibrosis in nonalcoholic fatty liver disease
by: Shahinul Alam, et al.
Published: (2016-07-01)

The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders
by: Miriam Longo, et al.
Published: (2024-01-01)

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients
by: Paola Dongiovanni, et al.
Published: (2019-06-01)

Phytosterols and phytostanols in context: From physiology and pathophysiology to food supplementation and clinical practice
by: Massimiliano Ruscica, et al.
Published: (2025-04-01)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis
by: Seong Hee Kang, et al.
Published: (2023-01-01)

Noninvasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease
by: Yu.M. Stepanov, et al.
Published: (2017-09-01)

Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease
by: Hannes Hagström, et al.
Published: (2018-01-01)

Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis
by: Wolhwa Song, et al.
Published: (2023-01-01)

Serum folate associated with nonalcoholic fatty liver disease and advanced hepatic fibrosis
by: Hao-Kai Chen, et al.
Published: (2023-08-01)

Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
by: David Bernstein, et al.
Published: (2022-03-01)

Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
by: Gwyneth Shook Ting Soon, et al.
Published: (2021-01-01)

Role of mast cells in the pathogenesis of liver fibrosis in nonalcoholic fatty liver disease
by: Ewa Lewandowska, et al.
Published: (2020-05-01)

Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
by: Min Chul Kim, et al.
Published: (2020-01-01)